T2D subphenotypes respond differently to T2D remission after MBS with SIDD showing a significantly lower remission rate than MOD and SIRD at 2 years. Considering metabolic status in treatment decisions may improve patient outcomes.
Poljo et al. (Sun,) studied this question.